Twitter is notable for plenty of things. Diagnosing breast cancer is not certainly one of them. Since the first National Breast Cancer Awareness Month in October 1985, millions of girls (and plenty of men too) have been influenced to take action inside the shape of a probably existence-saving mammogram—37 million are executed each year, which is tremendous. The problem is that awareness can also breed fiction, and our social feeds and email inboxes are particularly adept at spreading medical facts that aren’t exactly correct. Or even remotely accurate.
Here are 10 common breast cancer myths you want to stop believing, like, nowadays.
NEW YORK (GenomeWeb) – Agendia stated these days that it had signed an agreement with Valencia, Spain-based Imogen, for the specific distribution of Agendia’s MammaPrint and BluePrint breast most cancers genomic assessments in Spain and Portugal. MammaPrint measures the expression of 70 genes and classifies sufferers as either excessive threat or low hazard of recurrence over a 10-yr period. BluePrint is an eighty-gene assay that classifies sufferers as having both basal, luminal, or HER2 subtypes of breast most cancers to further manual treatments.
Both assessments are primarily based on the microarray era. Agenda additionally, one at a time, markets the MammaPrint and BluePrint Breast Cancer Recurrence and Molecular Subtyping Kits using the subsequent-era RNA sequencing era.
“We are very thrilled to have Imogen as a companion within the distribution of MammaPrint and BluePrint due to their information inside the vicinity of oncological genomics and experience in the Spanish market,” Agendia CEO Mark Straley said in a statement. “Together, we will bring our testing knowledge to the nearly 25,000 ladies annually identified with breast most cancers on the Iberian Peninsula.”Up to 70% of breast cancer survivors who have had mastectomies are unsure or unaware of their reconstruction options. The Alliance in Reconstructive Surgery (AiRS) Foundation is a non-profit organization dedicated to raising awareness and funds for women who have had mastectomies and cannot afford reconstructive surgery.
It was founded in 2012 by Janet Denlinger, Morgan Hare, and Dr. Rod Rohrich, who feel that while every woman might not want reconstructive surgery, they all should have a choice, regardless of their economic situation. To date, the foundation has helped over 100 women. A winner of the Saks Fifth Avenue Key for the Cure initiative in 2018, AiRS plans to double that number next year. The biggest challenge faced with AiRS is financing and reaching women who want to be educated about their reconstruction options and need financial help but don’t know that the non-profit exists. The foundation is working hard to reach out to these women through various methods, including establishing relationships with other organizations in the space such as Susan G. Komen, The American Cancer Society, Hospital Navigators, and the Patient Advocate Foundation.
AiRS cofounder Morgan Hare majored in science and worked in lab research before discovering her passion for marketing. She has held executive marketing, product development, and electronic retailing positions in skincare at several national consumer product companies, including Revlon, Avon, QVC, Home Shopping Network, Tupperware BeautiControl. With her dear friend of 44 years, Janet Denlinger, Hare launched the Heraclea skincare line in 2011, for which she serves as president.